503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Record LWR-ST-08 · South Region CERN/Zenodo DOI: 10.5281/zenodo.24139340 View Full 51-Jurisdiction Dataset →

Delaware (DE) GLP-1 Telehealth Access, Medicaid Coverage & Clinic Cost Audit (2026)

Empirical regulatory and out-of-pocket pricing benchmark for Delaware residents evaluating Semaglutide and Tirzepatide in 2026. In-person Delaware weight loss clinics average $485/mo (Semaglutide) and $690/mo (Tirzepatide), compared to verified flat-rate telehealth programs at $49/mo and $99/mo across all dosage tiers.

DE Local Med-Spa Median
$485/mo Sema
$690/mo local Tirzepatide median
Annual Flat-Rate Savings
$5,232/yr
$7,092/yr saved on Tirzepatide ($99/mo flat)
Commercial PA Denial Rate
43.2%
Adult obesity prevalence: 37.9%
DE Access Equity Score
80/100
2-day cold-chain pharmacy transit

2026 Delaware Telehealth & Coverage Matrix

Regulatory / Economic Dimension Delaware (DE) Verified Status Patient Impact
Initial Telehealth Exam Rule Live Audio-Video Telehealth Exam Required Patients complete a brief live video/audio check-in with a state-licensed clinician.
Adult Medicaid Obesity GLP-1 Coverage Covered (Strict PA & Step Therapy) Requires documented BMI & prior-authorization approval.
State Employee Health Plan GLP-1 Active Benefit Pathway Subject to plan-specific utilization management.
503A Sterile Pharmacy Licensing Tier Standard NABP Verified Non-Resident Pharmacy Reciprocity Cold-chain express delivery in ~2 business days statewide.
Semaglutide 12-Month Out-of-Pocket Local Clinic: $5,820/yr vs. Online Flat: $588/yr Saves $5,232/year ($0 monthly membership fee).
Tirzepatide 12-Month Out-of-Pocket Local Clinic: $8,280/yr vs. Online Flat: $1,188/yr Saves $7,092/year across 2.5 mg–15 mg tiers.

Primary Data Citation: Losing Weight RX Pharmacoeconomics & Consumer Audit Desk (2026). U.S. 50-State + D.C. Telehealth GLP-1 Prescribing Modality, Medicaid Coverage & Access Equity Matrix. DOI: 10.5281/zenodo.24139340 · State Reference: KFF DE State Health Facts.

Statewide Cold-Chain Delivery Across Delaware

Licensed partner pharmacies ship temperature-monitored vials to every residential ZIP code in Delaware (DE) within an estimated 2-business-day express window—eliminating multi-hour drives to regional weight management clinics.

Interactive Delaware GLP-1 Household Savings Estimator

Select your medication and treatment horizon to compare Delaware local clinic pricing against flat-rate online delivery:

Estimated DE Savings
$5,232
Local: $5,820 vs Flat Online: $588

Frequently Asked Questions — Delaware (DE)

Does Delaware Medicaid cover GLP-1 medications for adult weight loss in 2026?

Yes. As of November 2026, Delaware (DE) fee-for-service Medicaid maintains an active adult obesity GLP-1 pathway subject to strict prior authorization, BMI thresholds, and step-therapy documentation. Patients who do not qualify for Medicaid or face commercial prior-authorization denials (43.2% estimated initial denial rate in Delaware) frequently use self-pay flat-rate telehealth options starting at $49/mo for Semaglutide and $99/mo for Tirzepatide.

Is an online questionnaire allowed for GLP-1 telehealth prescriptions in Delaware?

Delaware medical board rules require live audio-video telehealth exam required before an initial prescription is issued. Partner telehealth networks automatically route Delaware residents into compliant synchronous clinician consultations at no extra membership charge.

How much do local weight loss clinics in Delaware charge compared to online flat-rate care?

Across Delaware, local in-person med-spas and cash bariatric clinics charge a median of $485/month for compounded Semaglutide and $690/month for compounded Tirzepatide. Switching to verified flat-rate online care ($49/mo Semaglutide, $99/mo Tirzepatide across all doses) saves Delaware households an estimated $5,232/year on Semaglutide or $7,092/year on Tirzepatide.

Insurance PA Denial vs. Cash-Pay Calculator → 52-Week Dose-Titration Cost Calculator → Read Full 50-State Empirical Study → Compare Online Providers →

Clinical & Regulatory References

The clinical efficacy, safety, and Delaware telehealth regulatory information in Delaware (DE) GLP-1 Telehealth Access, Medicaid Coverage & Clinic Cost Audit (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Delaware Division of Public Health. (2025). Public health, chronic disease, and clinical telehealth resources. https://dhss.delaware.gov/dph/
  2. Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022). Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. Journal of managed care & specialty pharmacy, 28(7), 740-752. https://doi.org/10.18553/jmcp.2022.28.7.740
  3. Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025). Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. Journal of managed care & specialty pharmacy, 31(5), 441-450. https://doi.org/10.18553/jmcp.2025.31.5.441
  4. MedlinePlus, National Library of Medicine. (2024). Telehealth: Overview and clinical guidance. https://medlineplus.gov/telehealth.html
  5. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
  6. Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, obesity & metabolism, 27(9), 5269-5279. https://doi.org/10.1111/dom.16580